AUTHOR=Zhou Lin , Zhan Wenyi , Wei Xin 

TITLE=Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1015338

DOI=10.3389/fphar.2022.1015338

ISSN=1663-9812

ABSTRACT=<p>Glaucoma is the main cause of irreversible visual loss worldwide, and comprises a group of progressive, age-related, and chronic optic neuropathies. Prostaglandin analogs are considered a first-line treatment in the management of glaucoma and have the best efficacy in reducing intraocular pressure. When comparing these therapeutic agents between them, long-term therapy with 0.03% bimatoprost is the most effective followed by treatment with 0.005% latanoprost and 0.004% travoprost. The prevalence of adverse events is lower for latanoprost than for other prostaglandin analogs. However, some patients do not respond to the treatment with prostaglandin analogs (non-responders). Intraocular pressure-lowering efficacy differs significantly between individuals partly owing to genetic factors. Rs1045642 in <italic>ABCB1</italic>, rs4241366 in <italic>SLCO2A1</italic>, rs9503012 in <italic>GMDS</italic>, rs10306114 in <italic>PTGS1</italic>, rs11568658 in <italic>MRP4</italic>, rs10786455 and rs6686438 in <italic>PTGFR</italic> were reported to be positive with the response to prostaglandin analogs in patients with glaucoma. A negative association was found between single nucleotide polymorphisms of <italic>PTGFR</italic> (rs11578155 and rs6672484) and the response to prostaglandin analogs in patients with glaucoma. The current review is an analysis of the information relevant to prostaglandin analog treatments based on previous literatures. It describes in detail the clinical pharmacology and pharmacogenetics of drugs belonging to this therapeutical class to provide a sound pharmacological basis for their proper use in ophthalmological clinical practice.</p>